Cover Image
市場調查報告書

過氧化體增生活化受體δ (PPARδ):開發平台分析

Peroxisome Proliferator-Activated Receptor Delta - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 359829
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
過氧化體增生活化受體δ (PPARδ):開發平台分析 Peroxisome Proliferator-Activated Receptor Delta - Pipeline Review, H1 2016
出版日期: 2016年05月18日 內容資訊: 英文 84 Pages
簡介

本報告提供以過氧化體增生活化受體δ為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

過氧化體增生活化受體δ概要

治療藥的開發

過氧化體增生活化受體δ:開發中的產品 - 各開發階段

過氧化體增生活化受體δ:開發中的產品 - 治療範圍別

過氧化體增生活化受體δ:開發中的產品 - 各適應症

過氧化體增生活化受體δ:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

過氧化體增生活化受體δ:企業開發中的產品

過氧化體增生活化受體δ:大學/機關開發中的產品

過氧化體增生活化受體δ:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

過氧化體增生活化受體δ的治療藥開發企業

  • Connexios Life Sciences Pvt. Ltd.
  • CymaBay Therapeutics, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • Inventiva
  • Mitobridge, Inc.
  • Nippon Chemipher
  • Plexxikon Inc.
  • T3D Therapeutics, Inc.
  • vTv Therapeutics LLC

藥物簡介

過氧化體增生活化受體δ:開發中止的產品

過氧化體增生活化受體δ:主要消息和新聞稿

附錄

目錄
Product Code: GMDHC0035TDB

Summary

Global Markets Direct's, 'Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016', provides in depth analysis on Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted pipeline therapeutics.

The report provides comprehensive information on the Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2)
  • The report reviews Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) Overview
    • Therapeutics Development
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Stage of Development
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Therapy Area
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Indication
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Companies
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Universities/Institutes
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Companies Involved in Therapeutics Development
    • Connexios Life Sciences Pvt. Ltd.
    • CymaBay Therapeutics, Inc.
    • Genfit SA
    • GlaxoSmithKline Plc
    • Inventiva
    • Mitobridge, Inc.
    • Nippon Chemiphar Co., Ltd.
    • Plexxikon Inc.
    • T3D Therapeutics, Inc.
    • vTv Therapeutics LLC
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Drug Profiles
    • CNX-013B2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elafibranor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GW-610742 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPP-593 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IVA-337 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NC-2400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target PPAR delta for Mitochondrial Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T3D-959 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Dormant Projects
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Discontinued Products
  • Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Featured News & Press Releases
    • Mar 31, 2016: GENFIT to Begin Elafibranor Clinical Program in PBC
    • Mar 30, 2016: Presentations at EASL/ILC 2016 Highlight Progress in NASH Treatment, Biomarker Diagnostics, and Programs Targeting Fibrotic Diseases
    • Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
    • Mar 10, 2016: GENFIT announces enrollment of first patient in RESOLVE-IT, the pivotal Phase 3 clinical trial of Elafibranor in NASH
    • Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress
    • Feb 11, 2016: Data from phase 2b trial of Genfit elafibranor published in Gastroenterology
    • Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge
    • Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input
    • Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
    • Jun 22, 2015: T3D Therapeutics Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer's Patients
    • Jun 08, 2015: T3D Therapeutics Selected by the Alzheimer's Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer's Association International Conference
    • Apr 24, 2015: New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion
    • Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
    • Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
    • Mar 26, 2015: Genfit Announces Topline Results From The Golden-505 Trial In Nash
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016
  • Pipeline by CymaBay Therapeutics, Inc., H1 2016
  • Pipeline by Genfit SA, H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Inventiva, H1 2016
  • Pipeline by Mitobridge, Inc., H1 2016
  • Pipeline by Nippon Chemiphar Co., Ltd., H1 2016
  • Pipeline by Plexxikon Inc., H1 2016
  • Pipeline by T3D Therapeutics, Inc., H1 2016
  • Pipeline by vTv Therapeutics LLC, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top